

Getting to Zero: Reducing HIV Incidence through Screening, Treatment, and Prevention

1. Centers for Disease Control and Prevention. HIV Surveillance Report, 2013; vol. 25. <http://www.cdc.gov/hiv/library/reports/surveillance/>. Published February 2015.
 - Slide 3, 4, 5, 6, 7, 8, 13, 14
2. Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas—2013. HIV Surveillance Supplemental Report 2015; 20 (No. 2). http://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report_vol20_no2.pdf. Published July 2015.
 - Slide 3, 17, 19, 40
3. CDC Infographics, www.cdc.gov/hiv/
 - Slide 6, 17
4. Centers for Disease Control and Prevention. Estimated HIV incidence in the United States, 2007– 2010. HIV Surveillance Supplemental Report 2012; 17 (No.4). http://www.cdc.gov/hiv/pdf/statistics_hssr_vol_17_no_4.pdf. Published December 2012.
 - Slide 9, 10, 12
5. Prejean J, Song R, Hernandez A, Ziebell R, Green T, et al. (2011) Estimated HIV Incidence in the United States, 2006–2009. PLoS ONE 6(8): e17502.
 - Slide 10
6. Millett GA, Flores SA, Peterson JL, Bakeman R. Explaining disparities in HIV infection among black and white men who have sex with men: a meta-analysis of HIV risk behaviors. AIDS. 2007 Oct 1; 21(15):2083-91.
 - Slide 11
7. Millett GA, Peterson JL, Flores SA, Hart TA, Jeffries WL 4th, Wilson PA, Rourke SB, Heilig CM, Elford J, Fenton KA, Remis RS. Comparisons of disparities and risks of HIV infection in black and other men who have sex with men in Canada, UK, and USA: a meta-analysis. Lancet. 2012 Jul 28; 380(9839):341-8.
 - Slide 11
8. Herbst JH, Jacobs ED, Finlayson TJ, McKleroy VS, Neumann MS, Crepaz N; HIV/AIDS Prevention Research Synthesis Team. Estimating HIV prevalence and risk behaviors of transgender persons in the United States: a systematic review. AIDS Behav. 2008 Jan; 12(1):1-17.
 - Slide 12

9. Baral SD, Poteat T, Strömdahl S, Wirtz AL, Guadamuz TE, Beyrer C. Worldwide burden of HIV in transgender women: a systematic review and meta-analysis. *Lancet Infect Dis*. 2013 Mar; 13(3):214-22.
 - Slide 12
10. Poteat T, Reisner SL, Radix A. HIV epidemics among transgender women. *Curr Opin HIV AIDS*. 2014 Mar; 9(2):168-73.
 - Slide 12
11. Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. *MMWR Recomm Rep*. 2015 Jun 5; 64(RR-03):1-137.
 - Slide 18, 19, 26, 27, 28
12. CDC. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. *MMWR Recomm Rep* 2006; 55(No. RR-14).
 - Slide 18, 19, 26, 27
13. Final Recommendation Statement: Human Immunodeficiency Virus (HIV) Infection: Screening. U.S. Preventive Services Task Force. May 2015.
<http://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/human-immunodeficiency-virus-hiv-infection-screening>
 - Slide 18
14. Zetola NM, Bernstein KT, Wong E, et al. Exploring the relationship between sexually transmitted diseases and HIV acquisition by using different study designs. *J Acquir Immune Defic Syndr* 2009; 50:546–51.
 - Slide 18
15. Centers for Disease Control and Prevention and Association of Public Health Laboratories. Laboratory Testing for the Diagnosis of HIV Infection: Updated Recommendations. Available at <http://dx.doi.org/10.15620/cdc.23447>. Published June 27, 2014.
 - Slide 20, 21, 23
16. Food and Drug Administration. OraQuick® In-Home HIV Test.2012. Available at: <http://www.fda.gov/biologicsbloodvaccines/bloodbloodproducts/approvedproducts/premarketapprovals/pmas/ucm310436.htm>.
 - Slides 20, 21
17. Walensky RP, Freedberg KA, Weinstein MC, Paltiel AD. Cost-effectiveness of HIV testing and treatment in the United States. *Clin Infect Dis*. 2007 Dec 15;45
 - Slide 24
18. Farnham PG, Hutchinson AB, Sansom SL, Branson BM. Comparing the costs of HIV screening strategies and technologies in health-care settings. *Public Health Rep*. 2008 Nov-Dec;123
 - Slide 24
19. Lyamuya EF, Aboud S, Urassa WK, Sufi J, Mbwana J, Ndugulile F, et al. Evaluation of simple rapid HIV assays and development of national rapid HIV test algorithms in Dar es Salaam, Tanzania. *BMC Infect Dis*. 2009; 9:19.
 - Slide 25

20. Viani RM, Araneta MR, Spector SA. Parallel rapid HIV testing in pregnant women at Tijuana General Hospital, Baja California, Mexico. *AIDS Res Hum Retroviruses*. 2012; 29(3):429–34.
 - Slide 25
21. Delaney KP, Branson BM, Uniyal A, Phillips S, Candal D, Owen SM, et al. Evaluation of the performance characteristics of 6 rapid HIV antibody tests. *Clin Infect Dis*. 2011; 52(2):257–63.
 - Slide 25
22. Zeh C, Oyaro B, Vandenhoudt H, Amornkul P, Kasembeli A, Bondo P, et al. Performance of six commercial enzyme immuno- assays and two alternative HIV- testing algorithms for the diagnosis of HIV-1 infection in Kisumu, Western Kenya. *J Virol Methods*. 2011; 176(1–2):24–31.
 - Slide 25
23. Choko AT, Desmond N, Webb EL, Chavula K, Napierala- Mavedzenge S, et al. The uptake and accuracy of oral kits for hiv self-testing in high hiv prevalence setting: a cross-sectional feasibility study in Blantyre, Malawi. *PLoS Med*. 2011; 8(10): e1001102.
 - Slide 25
24. Walensky RP, Bassett IV. HIV self-testing and the missing linkage. *PLoS Med*. 2011; 8(10):e1001101.
 - Slide 25
25. Mathews C, Coetzee N, Zwarenstein M, Lombard C, Guttmacher S, Oxman A, et al. A systematic review of strategies for partner notification for sexually transmitted diseases, including HIV/ AIDS. *Int J STD AIDS*. 2002; 13(5):285–300.
 - Slide 25
26. Centers for Disease Control and Prevention. Recommendations for partner services program for HIV infection, syphilis, gonorrhea and chlamydial infection. *MMWR Early Release* 2008; 57:1–64.
 - Slide 25
27. Cherutich P, Bunnell R, Mermin J. HIV testing: current practice and future directions. *Curr HIV/AIDS Rep*. 2013 Jun; 10(2):134-41.
 - Slide 25, 30
28. Zuckerman RA, Lucchetti A, Whittington WL, Sanchez J, Coombs RW, Zuñiga R, Margaret AS, Wald A, Corey L, Celum C. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. *J Infect Dis*. 2007 Nov 15;196(10)
 - Slide 26
29. Ackers ML, Greenberg AE, Lin CY, et al. High and persistent HIV seroincidence in men who have sex with men across 47 U.S. cities. *PLoS One* 2012; 7:e34972.
 - Slide 26

30. Denniston MM, Jiles RB, Drobeniuc J, et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. *Ann Intern Med* 2014; 160:293–300.223.
 - Slide 28
31. Fierer DS, Uriel AJ, Carriero DC, et al. Liver fibrosis during an outbreak of acute hepatitis C virus infection in HIV-infected men: a prospective cohort study. *J Infect Dis* 2008; 198:683–6.
 - Slide 28
32. Fierer DS, Mullen MP, Dieterich DT, et al. Early-onset liver fibrosis due to primary hepatitis C virus infection is higher over time in HIV- infected men. *Clin Infect Dis* 2012; 55:887–9.
 - Slide 28
33. Garg S, Taylor LE, Grasso C, et al. Prevalent and incident hepatitis C virus infection among HIV-infected men who have sex with men engaged in primary care in a Boston community health center. *Clin Infect Dis* 2013; 56:1480–7. 176.
 - Slide 28
34. Taylor LE, DeLong AK, Maynard MA, et al. Acute hepatitis C virus in an HIV clinic: a screening strategy, risk factors, and perception of risk. *AIDS Patient Care STDS* 2011; 25:571–7. 178.
 - Slide 28
35. Dionne-Odom J, Osborn MK, Radziewicz H, et al. Acute hepatitis C and HIV coinfection. *Lancet Infect Dis* 2009; 9:775–83.
 - Slide 28
36. van de Laar T, Pybus O, Bruisten S, et al. Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. *Gastroenterology* 2009; 136:1609–17.
 - Slide 28
37. Urbanus AT, van de Laar TJ, Stolte IG, et al. Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic. *AIDS* 2009; 23:F1–7.
 - Slide 28
38. Levy ME, Wilton L, Phillips G 2nd, Glick SN, Kuo I, Brewer RA, Elliott A, Watson C, Magnus M. Understanding structural barriers to accessing HIV testing and prevention services among black men who have sex with men (BMSM) in the United States. *AIDS Behav.* 2014 May; 18(5):972-96.
 - Slide 29
39. Hoover JB, Tao G, Heffelfinger JD. Monitoring HIV testing at visits to emergency departments in the United States: very-low rate of HIV testing. *J Acquir Immune Defic Syndr.* 2013 Jan 1; 62(1):90-4.
 - Slide 29

40. Haukoos JS, Hopkins E, Hull A, Dean C, Donahoe K, Ruzas CM, Bauerle JD, Terrien B, Forsyth J, Kalish B, Thrun M, Rothman R. HIV testing in emergency departments in the United States: a national survey. *Ann Emerg Med*. 2011 Jul; 58(1Suppl 1):S10-6.e1-8.
 - Slide 29
41. Korthuis PT, Berkenblit GV, Sullivan LE, et al. General internists' beliefs, behaviors, and perceived barriers to routine HIV screening in primary care. *AIDS Educ Prev*. 2011; 23(3 suppl): 70–83.
 - Slide 29
42. Zheng MY, Suneja A, Chou AL, Arya M. Physician barriers to successful implementation of US Preventive Services Task Force routine HIV testing recommendations. *J Int Assoc Provid AIDS Care*. 2014 May-Jun; 13(3):200-5.
 - Slide 29
43. Cherutich P, Bunnell R, Mermin J. HIV testing: current practice and future directions. *Curr HIV/AIDS Rep*. 2013 Jun; 10(2):134-41.
 - Slide 30
44. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. *N Engl J Med*. 2000; 342(13):921-929.
 - Slide 33
45. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. *N Engl J Med*. 2011; 365(6):493-505. Available
 - Slide 33, 34
46. Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. *PLoS One*. 2009; 4(5):e5575.
 - Slide 33
47. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at <http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf>.
 - Slide 33, 37
48. Grulich A et al. HIV transmission in male serodiscordant couples in Australia, Thailand and Brazil. 2015 Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, USA, abstract 1019LB, 2015.
 - Slide 35
49. INSIGHT START Study Group. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. *N Engl J Med*. 2015 Jul 20.
 - Slide 36
50. Data Safety and Monitoring Board. Strategic Timing of Antiretroviral Treatment Open Report. May 2015.
 - Slide 36

51. Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg MA, Infectious Diseases Society of America. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America. *Clin Infect Dis*. 2014 Jan; 58(1):e1-34.
 - Slide 38
52. Kapogiannis BG, Xu J, Mayer KH, et al. The HIV continuum of care for adolescents and young adults (12-24 years) attending 13 urban US centers of the NICHD-ATN-CDC-HRSA SMILE collaborative. IAS 2015. 8th Conference on HIV Pathogenesis, Treatment and Prevention. July 19-22, 2015. Vancouver. Abstract WELBPE16.
 - Slide 40
53. Ryan White Website: <http://hab.hrsa.gov/abouthab/aboutprogram.html>
 - Slide 42, 43
54. Kaiser Family Foundation. Health insurance coverage for people with HIV under the Affordable Care Act: Experiences in five states. December 19, 2014. <http://kff.org/hivaids/issue-brief/health-insurance-coverage-for-people-with-hiv-under-the-affordable-care-act-experiences-in-five-states/>
 - Slide 44
55. Kaiser Family Foundation. Assessing the impact of the Affordable Care Act on health insurance coverage of people with HIV. January 7, 2014. <http://kff.org/hivaids/issue-brief/assessing-the-impact-of-the-affordable-care-act-on-health-insurance-coverage-of-people-with-hiv/>
 - Slide 44
56. Blair JM, Fagan JL, Frazier EL, et al. Behavioral and Clinical Characteristics of Persons Receiving Medical Care for HIV Infection. *MMWR* 2014;63
 - Slide 48
57. Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission. *Cochrane Database Syst Rev*. 2002; 1(1):CD003255.16.
 - Slide 49
58. Smith DK, Herbst JH, Zhang X, Rose CE. Condom effectiveness for HIV prevention by consistency of use among men who have sex with men in the United States. *J AIDS*. 2015 Mar 1; 68(3):337-44.
 - Slide 49
59. Varghese B, Maher JE, Peterman TA, Branson BM, Steketee RW. Reducing the risk of sexual HIV transmission: quantifying the per-act risk for HIV on the basis of choice of partner, sex act, and condom use. *Sex Transm Dis* 2002; 29:38–43.93.
 - Slide 49
60. Cohen DA, Farley TA, Bedimo-Etame JR, Scribner R, Ward W, Kendall C, Rice J. Implementation of condom social marketing in Louisiana, 1993 to 1996. *Am J Public Health*. 1999 Feb; 89(2):204-8.
 - Slide 49

61. U.S. Department of Health and Human Services. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States. *MMWR Recomm Rep.* 2005 Jan 21; 54(RR02);1-20.
 - Slide 50, 51, 52
62. Centers for Disease Control and Prevention. Preexposure prophylaxis for the prevention of HIV infection in the United States. May 2014.
 - Slide 53, 54, 55, 56, 59
63. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. *N Engl J Med.* 2010; 363(27):2587-2599.
 - Slide 57
64. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. *N Engl J Med.* 2012; 367(5):399-410.
 - Slide 57
65. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. *N Engl J Med.* 2012; 367(5):423-434.
 - Slide 57
66. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. *N Engl J Med.* 2012; 367(5):411-422.
 - Slide 58
67. Marrazzo J, Ramjee G, Nair G, et al. (2013) Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the VOICE study (MTN 003) [Abstract]. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA.
 - Slide 58
68. Bekker LG, Hughes J, Amico R, et al. HPTN 067/ADAPT Cape Town: A Comparison of Daily and Nondaily PrEP Dosing in African Women. Abstract. CROI 2015.
 - Slide 60
69. Flash C, Landovitz R, Giler RM, Ng L, Magnuson D, Wooley SB, Rawlings K. Two years of Truvada for pre-exposure prophylaxis utilization in the US. *J Int AIDS Soc.* 2014 Nov 2; 17(4 Suppl 3):19730.
 - Slide 62, 63